NIH-sponsored trial of nasal COVID-19 vaccine opens

NIH-sponsored trial of nasal COVID-19 vaccine opens Candidate vaccine could provide enhanced breadth of protection against emerging SARS-CoV-2 variants. National Institutes of Health (NIH)

A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States. The National Institutes of Health (NIH) is sponsoring the first-in-human trial of the investigational vaccine, which was designed and tested in pre-clinical studies by scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Diseases.

...